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Abstract
Synovial fluid from patients with various arthritides contains
procoagulant, cell-derived microparticles. Here we studied
whether synovial microparticles modulate the release of
chemokines and cytokines by fibroblast-like synoviocytes (FLS).
Microparticles, isolated from the synovial fluid of rheumatoid
arthritis (RA) and arthritis control (AC) patients (n = 8 and n =
3, respectively), were identified and quantified by flow
cytometry. Simultaneously, arthroscopically guided synovial
biopsies were taken from the same knee joint as the synovial
fluid. FLS were isolated, cultured, and incubated for 24 hours in
the absence or presence of autologous microparticles.
Subsequently, cell-free culture supernatants were collected and
concentrations of monocyte chemoattractant protein-1 (MCP-
1), IL-6, IL-8, granulocyte/macrophage colony-stimulating factor
(GM-CSF), vascular endothelial growth factor (VEGF) and
intracellular adhesion molecule-1 (ICAM-1) were determined.
Results were consistent with previous observations: synovial
fluid from all RA as well as AC patients contained microparticles
of monocytic and granulocytic origin. Incubation with
autologous microparticles increased the levels of MCP-1, IL-8
and RANTES in 6 of 11 cultures of FLS, and IL-6, ICAM-1 and
VEGF in 10 cultures. Total numbers of microparticles were
correlated with the IL-8 (r = 0.91, P < 0.0001) and MCP-1
concentrations (r = 0.81, P < 0.0001), as did the numbers of
granulocyte-derived microparticles (r = 0.89, P < 0.0001 and r
= 0.93, P < 0.0001, respectively). In contrast, GM-CSF levels
were decreased. These results demonstrate that microparticles
might modulate the release of chemokines and cytokines by FLS
and might therefore have a function in synovial inflammation and
angiogenesis.
Introduction
Cell-derived microparticles, predominantly from platelets and
erythrocytes, are present in human blood. The presence of
such microparticles has been associated with the activation of
coagulation [1-3]. We demonstrated recently that synovial
fluid from the inflamed joints of rheumatoid arthritis (RA) and
arthritis control (AC) patients also contains cell-derived micro-
particles. These microparticles originate from monocytes and
granulocytes, and to a smaller extent from lymphocytes [4].
Synovial microparticles are strongly procoagulant via an initia-
tion mechanism dependent on tissue factor and factor VII(a).
We therefore proposed that such microparticles might con-
tribute to the local formation of fibrin clots, the so-called rice
bodies.
Fibroblast-like synoviocytes (FLS) have a key function in the
development of sustained inflammation and angiogenesis in
arthritic joints [5-8]. On activation in vitro by cytokines or bac-
terial lipopolysaccharides, FLS produce chemokines including
monocyte chemoattractant protein-1 (MCP-1) [9,10], IL-8
[11-13] and RANTES [11,14], cytokines such as IL-6 [12,13]
and granulocyte/macrophage colony-stimulating factor (GM-
CSF) [13,15,16], and angiogenic factors such as vascular
endothelial growth factor (VEGF) [17,18].
AC = arthritis control; ELISA = enzyme-linked immunosorbent assay; FCS = fetal calf serum; FLS = fibroblast-like synoviocytes; GM-CSF = granu-
locyte/macrophage colony-stimulating factor; IL = interleukin; mAb = monoclonal antibody; MCP = monocyte chemoattractant protein; PBS = phos-
phate-buffered saline; PE = phycoerythrin; RA = rheumatoid arthritis; sICAM-1 = soluble intracellular adhesion molecule 1; sPLA2 = secretory 
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The presence of leukocyte-derived microparticles in blood has
been associated with systemic inflammatory disorders, such
as pre-eclampsia [19], sepsis with multiple organ failure [20],
and meningococcal septic shock [21], and leukocyte-derived
microparticles – but not platelet-derived microparticles – trig-
ger the expression of IL-6 and MCP-1 by endothelial cells
[22,23]. However, it is unknown whether leukocytic micropar-
ticles contribute to local inflammation. We therefore deter-
mined whether isolated synovial microparticles of arthritis
patients trigger the release of (pro-) inflammatory and ang-
iogenic mediators by cultured autologous FLS from inflamed
joints of RA and AC patients.
Materials and methods
Patients
Paired synovial fluid, plasma and synovial tissue specimens
were collected from eight RA and three undifferentiated AC
patients. The diagnosis of AC patients stayed unchanged dur-
ing 1 year of follow-up. The RA patients fulfilled the criteria of
the 1987 Criteria of the American College of Rheumatology.
The study was approved by the Medical Ethical Committee of
the Academical Medical Center of the University of Amster-
dam, and informed consent was obtained to participate in the
present study. The demographic and clinical data are summa-
rized in Table 1.
Reagents and assays
Anti-CD4 labeled with phycoerythrin (PE; CLB-T4/2 6D10,
IgG1) and anti-CD66e-PE (CLB-gran/10 IH4Fc, IgG1) were
obtained from the Central Laboratory of the Netherlands Red
Cross Blood Transfusion Service (CLB; Amsterdam, The
Netherlands), anti-glycophorin A-PE (JC159, IgG1) was from
DakoCytomation (Glostrup, Denmark). Anti-CD8-PE (Leu™-
2a, IgG1), anti-CD14-PE (MφP9, IgG2b), anti-CD20-PE (L27,
IgG1), anti-CD61-PE (VI-PL2, IgG1) and IgG1-PE (X40) were
from Becton Dickinson (BD, San Jose, CA, USA), and anti-
IgG2b-PE (MCG2b) was from Immuno Quality Products (Gro-
ningen, The Netherlands). IL-6, IL-8 and intracellular adhesion
molecule-1 (ICAM-1; Diaclone Research, Besançon, France)
and MCP-1, RANTES, VEGF and GM-CSF (BioSource Inter-
national, Camarillo, CA, USA) were determined by ELISA. IL-
1β was obtained from Roche Diagnostics (Mannheim,
Germany)
Collection of the synovial biopsy and culture of FLS
Synovial tissue was collected from an actively inflamed joint by
small-needle arthroscopy under local anesthesia with a 2.5
mm biopsy forceps to sample from different areas throughout
the knee joint [24]. Synovial tissue was placed in Dulbecco's
modified Eagle's medium (Life Technologies, Paisley, Ren-
frewshire, UK) supplemented with 10% FCS, 50 µg/ml strep-
tomycin, 50 IU/ml penicillin and 2 mM L-glutamine and
subjected to tissue digestion within 2 hours, as described pre-
viously [25]. The cells were cultured at 37°C and 5% CO2.
After the second passage, FLS were seeded into 24-well flat-
bottomed plates (Costar, Acton, MA) and maintained for 24
hours in culture medium containing 1% FCS.
Collection of synovial fluid and blood samples
Immediately before the arthroscopy, we collected synovial
fluid (4.5 ml) from the same joint and also venous blood (4.5
ml) into tubes containing 0.5 ml of 3.2% sodium citrate (BD).
Immediately after collection, a further 0.5 ml of 3.2% sodium
citrate was added to the synovial fluid to prevent clotting. Cells
were removed from both blood and synovial fluid by
centrifugation for 20 min at 1,550 g and 20°C. For all determi-
nations, aliquots of cell-free plasma and synovial fluid were
snap-frozen in liquid nitrogen for at least 15 min and stored at
-80°C until use.
Microparticle isolation
For flow-cytometric analysis, cell-free synovial fluid aliquots
(250 µl) were thawed on melting ice and centrifuged for 30
min at 17,570 g and 20°C to pellet the microparticles. Super-
natant (225 µl) was removed and microparticles were resus-
pended in 225 µl PBS (154 mM NaCl, 1.4 mM phosphate, pH
7.4), containing 10.9 mM trisodium citrate. After centrifugation
for 30 min, supernatant (225 µl) was again removed and
microparticles were resuspended in 150 µl of PBS/citrate
buffer. For the FLS experiments, microparticles were isolated
from 1 ml of synovial fluid by centrifugation for 1 hour at
17,570 g and 20°C. Supernatant (975 µl) was removed and
replaced by 975 µl of PBS containing trisodium citrate. Micro-
particles were resuspended and again pelleted by centrifuga-
tion for 1 hour at 17,570 g  and 20°C. Again, 975 µl of
supernatant was removed and microparticles were resus-
pended in the remaining 25 µl. This microparticle suspension
was added to a final volume of 1 ml of culture medium in which
FLS had been maintained for 24 hours. Where indicated, a
higher concentration of microparticles was also tested for its
ability to activate FLS when sufficient synovial fluid was availa-
ble. These microparticles, isolated from 3 ml of synovial fluid,
were also concentrated into 25 µl of PBS containing trisodium
citrate. Microparticle suspensions were each added to FLS
cultures from the same donor to mimic the situation in vivo as
much as possible.
Incubation of FLS with microparticles
FLS were quiescent after incubation for 24 hours in medium
containing 1% FCS. After 24 hours, this medium (1 ml) was
replaced by culture medium containing 1% FCS without any
other addition (1 ml; control), or by 975 µl of culture medium
plus (1) 25 µl of IL-1β (125 pg/ml final concentration), (2) 25
µl of microparticle suspension or (3) 25 µl of microparticle-free
synovial fluid that had been diluted 1:9 in PBS (that is, contain-
ing 2.5 µl of the original synovial fluid; this quantity was chosen
arbitrarily to correct for both the onefold (unconcentrated) and
threefold concentrated microparticle suspensions that, after
washing of the microparticles, still contained about 0.7 and
2.1 µl of synovial fluid, respectively). Because individual FLSAvailable online http://arthritis-research.com/content/7/3/R536
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cultures showed a considerable variation in (mediator)
response to the positive control, namely IL-1β, we expressed
the response of each FLS culture to microparticles as a per-
centage of the IL-1β-induced response.
Flow-cytometric analysis
Microparticles were measured by flow cytometry with a
method that differed slightly from that used previously [4]. In
the present study, the microparticles were not washed by cen-
trifugation after being labeled with antibodies because this
resulted in a selective loss of microparticle populations. In
brief, 5 µl of the microparticle suspension was added to a mix-
ture of PBS (45 µl) containing 2.5 mM CaCl2 and 5 µl of PE-
labeled mAb, and incubated for 15 min in the dark at ambient
temperature (20 to 22°C). The following (final concentrations)
of mAbs were used: anti-CD4-PE (0.5 µg/ml), anti-CD8-PE
(0.25 µg/ml), anti-CD14-PE (0.25 µg/ml), anti-CD20-PE (0.5
µg/ml), anti-CD61-PE (0.5 µg/ml), anti-CD66e-PE (0.25 µg/
ml) and anti-glycophorin A-PE (0.25 µg/ml). PE-labeled IgG1
and IgG2b (both at 0.5 µg/ml) were used as isotype-specific
control antibodies. After incubation, 900 µl of PBS/CaCl2 was
added. Samples were analyzed on a FACSCalibur (BD) and
data were analyzed with CellQuest™ Pro software (version
4.02; BD). Both forward scatter and side scatter were set at
logarithmic gain. Microparticles w e r e  i d e n t i f i e d  b y  f o r w a r d
scatter, side scatter and binding of cell-specific mAb. The
number of microparticles per liter of plasma or synovial fluid
was estimated by using the number of events (N) of cell-spe-
cific mAb-binding microparticles after correction for control
antibody binding: number/liter = N × (150/5) × (955/67) ×
(106/250). The lower detection limit of the particle count was
previously established as 107 microparticles per liter. In this
formula, 150 (µl) is the final volume of the washed microparti-
cle suspension, 5 (µl) is the volume of this suspension that is
used for each labeling, 955 (µl) is the total volume of the
microparticle suspension after labeling before fluorescence-
activated cell sorting analysis, 67 (µl) is the average volume of
the labeled microparticle suspension that is analyzed by the
flow cytometer in 1 min, 106 is the conversion from µl to liter,
and 250 (µl) is the original volume of the plasma or synovial
fluid sample used for microparticle isolation.
Statistical analysis
Data were analyzed with GraphPad Prism for Windows,
release 3.02 (San Diego, CA, USA). Differences in the con-
centrations of chemokines, cytokines and VEGF between syn-
ovial fluid and plasma as well as in culture supernatants were
analyzed with the Wilcoxon signed-rank test. Two-tailed signif-
icance levels were considered significant at P < 0.05. All data
are presented as medians (range).
Results
Cellular origin of synovial microparticles
Previously, we found no differences between the numbers and
cellular origin of microparticles in synovial fluid from RA and
AC patients [4]. For all cell-specific antigens tested, the micro-
particle numbers of the three AC patients fell within the range
of the RA patients, which is consistent with these earlier
observations. The data in Table 2 therefore summarize the
microparticle numbers for RA and AC patients together. Most
microparticles originated from monocytes (CD14) and granu-
locytes (CD66e). Microparticles derived from platelets
(CD61) and erythrocytes (glycophorin A) were below detec-
tion level (less than 107/l) in synovial fluid from all patients,
except in one RA patient who had a low but detectable
number (1.7 × 107/l) of platelet-derived microparticles. One
Table 1
Demographic and clinical data of the rheumatoid arthritis patients and arthritis controls
Parameter RA patients (n = 8) AC patients (n = 3)
Age (years) 58 (34–69) 56 (49–68)
Sex (no. of males/females) 4/4 3/0
Disease duration (months) 60 (4–360) 2 (1–12)
Rheumatoid factor 7 positive; 1 negative 1 positive; 2 negative
Tender joint count 9 (5–15) 1 (1–2)
Swollen joint count 11 (5–19) 2 (1–23)
ESR (mm/h) 46 (25–69) 38 (28–43)
Erosive disease 6 positive; 2 negative None
No. of DMARDs 4.5 (1–5) 0
Leukocytes in SF (109/l) 6.3 (4.5–7.0) 4.3 (4.2–4.5)
CRP (mg/l) 34 (8–97) 4 (<3–26)
Results are medians, with ranges in parentheses. AC, arthritis control; CRP, C-reactive protein in plasma; DMARDs, disease-modifying 
antirheumatic drugs; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; SF, synovial fluid.Arthritis Research & Therapy    Vol 7 No 3    Berckmans et al.
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other RA patient had a relatively high number of erythrocyte-
derived microparticles (3.1 × 109/l). Microparticles from CD4+
cells were found in six RA patients and all AC patients. Micro-
particles from CD8+ T cells were present in the synovial fluid
of five RA patients and one AC patient. Microparticles from B
cells were found in two RA patients only.
Synovial microparticles stimulate FLS
FLS were quiescent after incubation for 24 hours in medium
containing 1% FCS. The concentrations of all markers studied
in the FLS culture supernatants are summarized in Table 3. In
comparison with the control (unstimulated), IL-1β significantly
increased the levels of all mediators tested, whereas the addi-
tion of microparticle-free synovial fluid affected especially the
soluble ICAM-1 (sICAM-1) levels. This increase was due to its
presence in the synovial fluid itself. Addition of microparticles
to FLS significantly increased the levels of MCP-1 (P  =
0.010), sICAM-1 (P = 0.010), IL-8 (P = 0.008), IL-6 (P =
0.042), VEGF (P = 0.001) and RANTES (P = 0.031). In con-
trast, the concentrations of GM-CSF decreased (P = 0.002).
In six patients (three RA and three AC patients), we also tested
a threefold higher (final) concentration of synovial microparti-
cles. In comparison with the 'onefold' concentration, levels of
sICAM-1 (P = 0.031), IL-8 (P = 0.031) and IL-6 (P = 0.031)
increased further and GM-CSF (P = 0.016) decreased further
(Table 3). Levels of MCP-1 (P = 0.156), VEGF (P = 0.078)
and RANTES (P = 0.062) also tended to increase further, but
these differences did not reach statistical significance.
Because individual microparticle suspensions were tested in
(autologous) FLS cultures and considerable differences were
observed in the responsiveness of these individual cell cul-
tures, the individual responses of FLS cultures are also shown
(Fig. 1). The response is expressed as either an increase or a
decrease relative to the control, namely the 24-hour incubation
of FLS with the microparticle-free synovial fluid. Although vari-
ation between FLS cultures is apparent, the individual data
substantiate the conclusions above as based on group
analysis.
Concentrations of MCP-1, IL-6, IL-8, RANTES, sICAM-1, 
VEGF and GM-CSF in vivo
For comparison, the concentrations of the various mediators
were also determined in both synovial fluid and plasma from
RA and AC patients. Because only 2 values (of 36) of the AC
patients fell outside the RA range, namely MCP-1 in synovial
fluid and sICAM-1 in plasma from the same AC patient, all data
are summarized in Table 4. In comparison with plasma, levels
of MCP-1 (P = 0.008), IL-6 (P = 0.002), IL-8 (P = 0.002) and
VEGF (P = 0.002) were elevated in synovial fluid, those of
RANTES and ICAM-1 were decreased (P = 0.001 and P =
0.006, respectively), and GM-CSF concentrations were simi-
lar (P = 0.125). Figure 2 shows that both the total number of
microparticles (Fig. 2a; r = 0.91; P < 0.0001) and the num-
bers of granulocyte-derived microparticles (Fig. 2b; r = 0.89,
P < 0.0001) were correlated with the IL-8 concentrations,
whereas the numbers of monocyte-derived microparticles
were not (Fig. 2c; r = 0.04; P = 0.89). In addition, concentra-
tions of MCP-1 were correlated with total numbers of micro-
particles (r = 0.81, P < 0.0001) and numbers of granulocyte-
derived microparticles (r = 0.93, P < 0.0001), but again not
with the numbers of monocyte-derived microparticles (r  =
0.06; P = 0.82; data not shown). No other correlations were
found between microparticle numbers and concentrations of
mediators.
Discussion
The present study shows that synovial fluid microparticles trig-
ger FLS to release chemokines, cytokines and other mediators
of inflammation. The extent to which these changes are solely
induced by microparticles remains to be shown. We cannot
exclude from our present data the possibility that the activation
of FLS is due in part to synergistic actions of the microparti-
cles with one or more mediators released by FLS themselves
under these conditions. Neither can we exclude the possibility
that microparticles activate FLS in synergy with one or more
Table 2
Microparticle numbers in synovial fluid from patients with arthritic joints
Origin mAb Synovial fluid
CD4+ cells CD4 191 (<10–711)
CD8+ cells CD8 <10 (<10–331)
Monocytic cells CD14 1,315 (57–13,326)
B-cells CD20 <10 (<10–104)
Platelets CD61 <10 (<10–17)
Erythrocytes Glycophorin A <10 (<10–3,104)
Granulocytes CD66e 2,380 (<10–20,864)
Results are medians, with ranges in parentheses. Data are the numbers (× 106/l) of marker-positive microparticles from all arthritic patients (n = 
11).Available online http://arthritis-research.com/content/7/3/R536
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Figure 1
Responses of individual cultures of fibroblast-like synoviocytes from rheumatoid arthritis (RA; n = 8) and arthritis control (AC; n = 3) patients to their  autologous synovial microparticles Responses of individual cultures of fibroblast-like synoviocytes from rheumatoid arthritis (RA; n = 8) and arthritis control (AC; n = 3) patients to their 
autologous synovial microparticles. All individual patient data for the markers studied are expressed as the concentration of the mediator in the pres-
ence of microparticles concentrated either onefold (black bars) or threefold (open bars) divided by the concentration of mediator in the presence of 
microparticle-free synovial fluid. ICAM-1, intracellular adhesion molecule-1; MCP-1, monocyte chemoattractant protein-1.
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Table 3
Effect of synovial microparticles on the release of inflammatory mediators by fibroblast-like synoviocytes from arthritic patients (n 
= 11)
Mediator Control P* MP-free synovial 
fluid
MP (1×) Nx/Nt P† MP (3×) Nx/Nt P‡
Unstimulated IL-1β
MCP-1 (pg/ml) 456 4,754 0.001 469 488 6/11 0.010 900 4/6 0.156
(355–1,292) (2,492–6,081) (293–1,241) (338–1,481) higher (346–2,326) higher
sICAM-1 (ng/ml) 0.09 0.40 0.007 1.04 2.00 8/11 0.010 6.07 6/6 0.031
(0–0.3) (0–0.76) (0.34–1.84) (0.35–4.07) higher (0.91–11.75) higher
IL-8 (pg/ml) 0 8,642 0.001 26 301 5/11 0.008 790 6/6 0.031
(0–564) (2,954–18,330) (0–528) (0–707) higher (0–2,100) higher
IL-6 (pg/ml) 74 4949 0.001 110 136 7/11 0.042 436 6/6 0.031
(24–1,710) (1,870–22,797) (30–1,176) (34–1,937) higher (44–3,766) higher
VEGF (pg/ml) 48 79 0.014 34 74 10/11 0.001 111 6/6 0.078
(11–102) (7–141) (1–97) (28–138) higher (27–161) higher
GM-CSF (pg/ml) 32 53 0.004 31 22 10/11 0.002 18 6/6 0.016
(28–40) (40–72) (26–70) (14–43) lower (14–25) lower
RANTES (pg/ml) 0 138 0.001 0 0.2 4/11 0.031 4.2 5/6 0.062
(0–74) (46–277) (0–58) (0–86) higher (0–32) higher
Results are medians, with ranges in parentheses. Concentrations of mediators were determined in the culture supernatant of the fibroblast-like 
synoviocytes (FLS) by ELISA as described in the Materials and methods section. FLS were incubated for 24 hours with 1 ml of culture medium 
containing 1% FCS (negative control), 975 µl of culture medium supplemented with either (1) 25 µl of interleukin (IL)-1β (final concentration 125 
pg/ml; positive control), (2) 25 µl (onefold (1×) or threefold (3×) concentrated) microparticles (MP), or (3) MP-free synovial fluid. P*, positive versus 
negative control; P†, MP (1×) versus MP-free synovial fluid; P‡, MP (3×) versus MP (1×). Nx/Nt, number of individual culture supernatants that 
contained elevated or decreased concentrations of mediators after incubation for 24 hours with isolated MP compared with MP-free synovial fluid, 
divided by the number of patients studied. GM-CSF, granulocyte/macrophage colony-stimulating factor; sICAM-1, soluble intracellular adhesion 
molecule-1; MCP-1, monocyte chemoattractant protein-1; VEGF, vascular endothelial growth factor.
Table 4
Concentrations of inflammatory mediators in synovial fluid and plasma from arthritic patients (n = 11)
Mediator Concentration P
Synovial fluid Plasma
MCP-1 (pg/ml) 134 (36–522) 34 (15–62) 0.008
sICAM-1 (ng/ml) 706 (226–1,085) 871 (657–1,691) 0.006
IL-8 (pg/ml) 614 (<50–24,630) <50 0.002
IL-6 (pg/ml) 13,897 (35–43,131) 11 (0–57) 0.002
VEGF (pg/ml) 1,604 (528–2,506) 23 (<5–69) 0.002
RANTES (pg/ml) 7 (<5–35) 3,986 (2,920–10,037) 0.001
GM-CSF (pg/ml) <2 (<2–39) <2 (<2–28) 0.125
Results are medians, with ranges in parentheses. Concentrations of all mediators were determined by ELISA as described in the Materials and 
methods section. GM-CSF, granulocyte/macrophage colony-stimulating factor; MCP-1, monocyte chemoattractant protein-1; sICAM-1, soluble 
intracellular adhesion molecule-1; VEGF, vascular endothelial growth factor.Available online http://arthritis-research.com/content/7/3/R536
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mediators already present in the synovial fluid. Nevertheless,
the release of IL-8 and MCP-1 was correlated directly to both
the total number of microparticles and the number of granulo-
cyte-derived microparticles. This suggests that microparticles
might trigger FLS to release these mediators. Although no cor-
relations were found between microparticle numbers and
sICAM-1, IL-6, VEGF and RANTES, a threefold increased con-
centration of microparticles tended to induce a higher
response.
On the basis of these data it is tempting to speculate that syn-
ovial fluid microparticles promote synovial inflammation and
neoangiogenesis in arthritic joints. The FLS are localized in the
intimal lining layer, which directly contacts the synovial fluid
compartment. Thus, synovial fluid microparticles may interact
directly with the FLS, thereby modulating the release of an
array of proinflammatory cytokines and chemokines. This may
lead to further cell activation, neoangiogenesis and cell recruit-
ment, constituting a proinflammatory amplification loop. Con-
sistent with this notion is the observation that the removal of
synovial fluid by arthroscopic lavage has a positive therapeutic
effect in RA [26]. In addition, it has previously been shown that
intra-articular injection of corticosteroids is more effective after
arthrocentesis [27]. This has been explained by the effects of
removal of fluid containing various proinflammatory cytokines.
At present, we can only speculate how synovial microparticles
trigger FLS to produce and/or release proinflammatory media-
tors. Synovial microparticles originate mainly from leukocytes
[4]. In vitro, leukocytic microparticles trigger the release of IL-
6 and MCP-1 from endothelial cells [22,23]. Microparticles
can contain bioactive lipids such as oxidized phospholipids,
arachidonic acid and lysophosphatidic acid [28,29]. In partic-
ular, both arachidonic acid and lysophosphatidic acid are
present in microparticles previously exposed to secretory
phospholipase A2 (sPLA2) [30]. Arachidonic acid is trans-
ferred directly from microparticles to endothelial cells, result-
ing in the production of IL-6 [29]. It is unknown whether
lysophosphatidic acid, a multifunctional lipid mediator that
induces cell proliferation, migration and survival, is also directly
transferred [31]. Synovial microparticles have been exposed
to high levels of sPLA2 in vivo and are therefore likely to con-
tain elevated levels of bioactive lipids. Thus, we propose that
synovial microparticles might directly transfer bioactive lipids
to FLS, thereby modulating the production and/or release of
proinflammatory mediators. For this transfer, a direct interac-
tion between microparticles and the FLS is essential. Because
microparticles expose an array of cell-type-specific adhesion
receptors, a direct interaction is likely. Alternatively, we cannot
exclude the possibility that synovial microparticles might also
contain inflammatory cytokines, because monocyte-derived
microparticles generated in vitro were recently demonstrated
to contain IL-1β [32].
Finally, the present study again showed that elevated levels of
microparticles from granulocytes, monocytes and lym-
phocytes are present in the synovial fluid of arthritic patients.
At present it is unknown why such elevated numbers of micro-
particles occur under these conditions. Apoptotic cells expose
phosphatidylserine. Macrophages expose phosphatidylserine
receptors, which efficiently initiate the recognition and subse-
quent removal of apoptotic cells [33,34]. It is also likely that
Figure 2
Correlation between microparticle numbers and IL-8 concentrations Correlation between microparticle numbers and IL-8 concentrations. 
Correlations are shown between IL-8 produced by FLS in response to 
total microparticles (a), granulocyte-derived microparticles (b) and 
monocyte-derived microparticles (c). Note that data obtained with FLS 
in response to onefold and threefold concentrated microparticle sus-
pensions are included.
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microparticles are removed from the circulation by means of
such receptors. However, synovial microparticles bind less
annexin V than microparticles from plasma [4]. This decreased
binding is due either to a decreased exposure of
phosphatidylserine or to the presence of high levels of sPLA2,
which competes with annexin V for binding to phosphatidylser-
ine [35,36]. The removal of microparticles by phagocytic cells
might thus be impaired in inflamed joints, resulting in the pro-
longed presence of microparticles and therefore in the contin-
ued stimulation of the FLS.
Conclusion
The results of the present study suggest that microparticles
modulate the release of chemokines and cytokines by FLS.
However, their biological relevance, compared with or in syn-
ergy with other biological mediators in synovial fluid, remains
to be determined. The beneficial effect of arthrocentesis and
arthroscopic lavage in RA might be explained, at least in part,
by the removal of synovial fluid microparticles.
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